Emily Bosiacki ’21
Majors: Biology and Psychology
Faculty Mentor: Dr. Victoria Templer, Psychology
3,4-Methamphetamine (METH) has not been studied as a treatment method for people who have Antisocial Personality Disorder (ASPD). ASPD is mainly characterized by a lack of cognitive and emotional empathy. Previous research expresses that emotional empathy is achievable through drug treatment with empathogens such as ecstacy and psilocybin, but there has been no successful treatment to improve cognitive empathy. METH has not been used in previous research due it being very addictive and detrimental to cognitive function if taken at high levels over an extended period of time. Microdosing METH shows promising results in patients with attention deficit hyperactivity disorder (ADHD). Using this previous research to understand effective dosing and symptoms of microdosing METH, a promising treatment could be established for ASPD participants. For patients taking METH, users report having higher levels of sociability. With an increase in sociability, it is hypothesized that there will be an increase in cognitive empathy as well. This will be tested through the use of the Multifaceted Empathy Test (MET) which specifically measures cognitive empathy, and the Empathy Quotient (EQ) which analyzes both emotional empathy and cognitive empathy. It is hypothesized that during pre-treatment, participants in the treatment group receiving METH, will show an average score for the EQ and report emotions of others at least 50% correctly for the MET, while the control group will continue to score below average for their EQ and will report emotions of others below 50% correctly for the MET.
4-29-2021 12:00 AM